Use of SGLT2 Inhibitors and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists in Australian Primary Care Patients with Type 2 Diabetes Mellitus (T2DM) Stratified by CKD Status

Authors: Hannah Wallace, James Wick, Daniel Bekele Ketema, Brendon Lange Neuen, Meg Jardine, Jialing Lin, Craig L. Nelson, Sallie Pearson, David Peiris, Mark Woodward, Paul E. Ronksley, Martin P. Gallagher, Sradha S. Kotwal, Min Jun

Published: 2024-10-28

DOI: 10.1681/asn.2024f7q40fk1

Keywords: No keywords found.

Abstract:
No abstract found.

Source: